Abstract
Tuberous sclerosis complex (TSC) is a genetic condition characterized by the growth of benign tumours in multiple organs, including the brain and kidneys, alongside intellectual disability and seizures. Identification of a causative mutation in TSC1 or TSC2 is important for accurate genetic counselling in affected families, but it is not always clear from genetic data whether a sequence variant is pathogenic or not. In vitro functional analysis could provide support for determining whether an unclassified TSC1 or TSC2 variant is disease-causing. We have performed a detailed functional analysis of four patient-derived TSC2 mutations, E92V, R505Q, H597R and L1624P. One mutant, E92V, functioned similarly to wild-type TSC2, whereas H597R and L1624P had abnormal function in all assays, consistent with available clinical and segregation information. One TSC2 mutation, R505Q, was identified in a patient with intellectual disability, seizures and autistic spectrum disorder but who did not fulfil the diagnostic criteria for TSC. The R505Q mutation was also found in two relatives, one with mild learning difficulties and one without apparent phenotypic abnormality. R505Q TSC2 exhibited partially disrupted function in our assays. These data highlight the difficulties of assessing pathogenicity of a mutation and suggest that multiple lines of evidence, both genetic and functional, are required to assess the pathogenicity of some mutations.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305–1315.
van Slegtenhorst M, de Hoogt R, Hermans C et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805–808.
Jones AC, Shyamsundar MM, Thomas MW et al: Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64: 1305–1315.
Dabora SL, Jozwiak S, Franz DN et al: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: 64–80.
Sancak O, Nellist M, Goedbloed M et al: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 2005; 13: 731–741.
Sue Povey and Rosemary Ekong (2005-2009). Tuberous sclerosis database. LOVD v.2.0, http://chromium.liacs.nl/LOVD2/TSC/home.php?select_db=TSC2.
Beauchamp RL, Banwell A, McNamara P et al: Exon scanning of the entire TSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis. Hum Mutat 1998; 12: 408–416.
Bell J, Bodmer D, Sistermans E, Ramsden S : Practice guidelines for the Interpretation and Reporting of Unclassified Variants (UVs) in Clinical Molecular Genetics, 2007, www.cmgs.org/BPGs/pdfs%20current%20bpgs/UV%20GUIDELINES%20ratified.pdf.
Mozaffari M, Hoogeveen-Westerveld M, Kwiatkowski D et al: Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. BMC Med Genet 2009; 10: 88.
Nellist M, van den Heuvel D, Schluep D et al: Missense mutations to the TSC1 gene cause tuberous sclerosis complex. Eur J Hum Genet 2009; 17: 319–328.
Coevoets R, Arican S, Hoogeveen-Westerveld M et al: A reliable cell-based assay for testing unclassified TSC2 gene variants. Eur J Hum Genet 2009; 17: 301–310.
Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J : Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002; 99: 13571–13576.
Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D : Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578–581.
Garami A, Zwartkruis FJ, Nobukuni T et al: Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: 1457–1466.
Inoki K, Li Y, Xu T, Guan KL : Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17: 1829–1834.
Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J : Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259–1268.
Jones AC, Sampson JR, Hoogendoorn B Cohen D, Cheadle JP : Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet 2000; 106: 663–668.
Schalm SS, Blenis J : Identification of a conserved motif required for mTOR signalling. Curr Biol 2002; 12: 632–639.
Dunlop EA, Dodd KM, Seymour LA, Tee AR : Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cell Signal 2009; 21: 1073–1084.
Roach ES, Gomez MR, Northrup H : Tuberous Sclerosis Complex Consensus Conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624–628.
Land SC, Tee AR : Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007; 282: 20534–20543.
Cai SL, Tee AR, Short JD et al: Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 2006; 173: 279–289.
Schalm SS, Fingar DC, Sabatini DM, Blenis J : TOS Motif-mediated raptor binding regulates 4E-bp1multisite phosphorylation and function. Curr Biol 2003; 13: 797–806.
Hara K, Maruki Y, Long X et al: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177–189.
Cotton RG, Auerbach AD, Axton M et al: The Human Variome Project. Science 2008; 322: 861–862.
Acknowledgements
This work was supported by the Association for International Cancer Research Career Development Fellowship (no. 06-914/915; to A Tee), the Tuberous Sclerosis Association and Wales Gene Park. We also thank the All Wales Medical Genetics Service.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on European Journal of Human Genetics website
Rights and permissions
About this article
Cite this article
Dunlop, E., Dodd, K., Land, S. et al. Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence. Eur J Hum Genet 19, 789–795 (2011). https://doi.org/10.1038/ejhg.2011.38
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2011.38
